Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22916980 | 0.90 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2TSHRPOLB | |
| SCHEMBL22916938 | 0.86 | MEN1 (0.49) | KMT2AMEN1SMN1; SMN2TSHRPOLB | |
| SCHEMBL888973 | 0.80 | CYP3A4 (0.49) | KMT2AMEN1SMN1; SMN2TSHRPOLB | |
| SCHEMBL12755260 | 0.80 | CYP3A4 (0.49) | KMT2AMEN1SMN1; SMN2TSHRPOLB | |
| SCHEMBL26073815 | 0.80 | MEN1 (0.55) | KMT2AMEN1SMN1; SMN2TSHRPOLB | |
| SCHEMBL21097014 | 0.80 | MEN1 (0.55) | KMT2AMEN1SMN1; SMN2TSHRPOLB | |
| SCHEMBL12233572 | 0.79 | XPNPEP2 (0.45) | KMT2AMEN1POLBMAPTLMNA | |
| SCHEMBL3283616 | 0.79 | XPNPEP2 (0.45) | KMT2AMEN1POLBMAPTLMNA | |
| SCHEMBL17636777 | 0.79 | CHRNB2 (0.44) | KMT2AMEN1SMN1; SMN2ALDH1A1CHRNB2 | |
| SCHEMBL14348122 | 0.78 | SMN1; SMN2 (0.54) | KMT2AMEN1SMN1; SMN2TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | KMT2A 2349/4885MEN1 41/4885SMN1; SMN2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.